IFRX News

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

InflaRx to Report Full Year 2025 Results on March 19, 2026

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

B&F Contracting Chooses InEight Project Controls Software for End-To-End Project Visibility

InflaRx Announces Participation in February Investor Conferences

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

Organic & Natural Health to Address Policy, Integrity and Innovation at 2026 Industry Conference